Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | PGK1 | P00558 | 7/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855929 | 0.79 | TNF (0.42) | MAP4K4GSK3BKDM4ELMNA | |
| SCHEMBL22440558 | 0.79 | KDM4E (0.39) | KDM4EALDH1A1LMNA | |
| SCHEMBL21856005 | 0.78 | UTS2R (0.46) | UTS2RGSK3BKDM4EALDH1A1CYP1A2 | |
| SCHEMBL19387107 | 0.78 | UTS2R (0.40) | UTS2RPGK1MAP4K4KDM4EALDH1A1 | |
| SCHEMBL22493746 | 0.75 | IDH1 (0.32) | KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL741028 | 0.75 | GOT1 (0.33) | ALDH1A1 | |
| SCHEMBL29563486 | 0.74 | KDM4E (0.30) | KDM4EALDH1A1LMNA | |
| SCHEMBL21920610 | 0.74 | LRRK2 (0.41) | MAP4K4KDM4EHPGDGRM5LMNA | |
| SCHEMBL30133420 | 0.74 | CLK4 (0.50) | KDM4EALDH1A1HPGD | |
| SCHEMBL24152599 | 0.74 | ACACB (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289753-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-09-15 | — | — | US | disclosed |
| CN-114728935-A | SHP2 inhibitor | IRBM股份公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4010335-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-06-15 | — | — | EP | disclosed |
| EP-3947367-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | Array Biopharma, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021028362-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028362-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2021-02-18 | — | — | WO | disclosed |
| WO-2020201991-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289753-A1 | SHP2 INHIBITORS | PTPN1, PTPN2, PTPN7 | UTS2R 2504/4885PGK1 1199/4885MAP4K4 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.